Precigen (NASDAQ:PGEN) Director Randal Kirk Sells 942,832 Shares

Precigen, Inc. (NASDAQ:PGEN) Director Randal Kirk sold 942,832 shares of Precigen stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $4.08, for a total value of $3,846,754.56. Following the sale, the director directly owned 6,491,552 shares in the company, valued at $26,485,532.16. The trade was a 12.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Precigen Trading Down 0.5%

Shares of NASDAQ:PGEN traded down $0.02 during midday trading on Friday, hitting $3.88. 4,626,470 shares of the stock were exchanged, compared to its average volume of 4,540,987. The business’s 50-day moving average price is $3.82 and its 200 day moving average price is $2.71. Precigen, Inc. has a 12 month low of $0.65 and a 12 month high of $5.22. The company has a debt-to-equity ratio of 2.22, a quick ratio of 3.95 and a current ratio of 4.04. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -2.79 and a beta of 1.71.

Precigen (NASDAQ:PGEN) last posted its earnings results on Thursday, November 13th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Precigen had a positive return on equity of 1,066.10% and a negative net margin of 3,912.92%.The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $0.67 million. Analysts predict that Precigen, Inc. will post -0.32 earnings per share for the current year.

Institutional Trading of Precigen

A number of large investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd bought a new position in shares of Precigen in the 3rd quarter worth about $39,000. Russell Investments Group Ltd. bought a new stake in shares of Precigen during the 3rd quarter valued at about $41,000. Vontobel Holding Ltd. acquired a new stake in Precigen during the third quarter worth approximately $48,000. CIBC Bancorp USA Inc. bought a new stake in Precigen in the third quarter worth approximately $53,000. Finally, Voya Investment Management LLC increased its holdings in Precigen by 142.9% in the first quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 21,633 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on PGEN. Wall Street Zen cut shares of Precigen from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. HC Wainwright lifted their target price on Precigen from $8.50 to $9.00 and gave the stock a “buy” rating in a report on Friday, November 14th. JMP Securities increased their price target on Precigen from $6.00 to $8.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Wednesday, October 8th. Finally, Citigroup reiterated an “outperform” rating on shares of Precigen in a report on Tuesday, August 19th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Precigen presently has an average rating of “Moderate Buy” and an average price target of $8.50.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.